BIOA-B.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:10):

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden...

Stats
Today's Volume	81 250.00
Average Volume	159 454
Market Cap	17.54B
EPS	SEK0 ( 2024-02-14 )
Next earnings date	( SEK-0.750 ) 2024-05-17
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	76.47
ATR14	SEK0.320 (0.16%)

Volume Correlation

Long: 0.04 (neutral)

Short: -0.61 (weak negative)

Signal:(65.782) Neutral

BioArctic AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioArctic AB (publ) Correlation - Currency/Commodity

-0.33
( neutral )

-0.34
( neutral )

-0.49
( neutral )

-0.56
( weak negative )

-0.40
( neutral )

0.32
( neutral )

BioArctic AB (publ) Financials

Annual	2023
Revenue:	SEK616.00M
Gross Profit:	SEK346.32M (56.22 %)
EPS:	SEK2.60

FY	2023
Revenue:	SEK616.00M
Gross Profit:	SEK346.32M (56.22 %)
EPS:	SEK2.60

FY	2022
Revenue:	SEK228.29M
Gross Profit:	SEK153.97M (67.44 %)
EPS:	SEK-0.130

FY	2021
Revenue:	SEK23.15M
Gross Profit:	SEK-31.92M (-137.91 %)
EPS:	SEK-1.360

Financial Reports:

No articles found.

BioArctic AB (publ)

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.